Reflections of 2022
As the end of the year approaches, I’m reflecting on all the stories shared by our Medtronic community on what’s been most challenging, and importantly the wins we’ve celebrated along the way. Those have been the most uplifting moments for me personally and I wanted to thank you for not only warmly welcoming me into this vibrant community but allowing me to be a small part of your journey. Living with diabetes is no small feat – it takes emotional stamina, resilience, and grit. During my seven months at Medtronic, I’ve had the honor of meeting many extraordinary people who live with diabetes and today, I’d like to share some of their stories with you.
Meet Missy and Blythe from the United States
A mother and daughter duo bravely manages their diabetes journey together – through the highs and lows, the carb counting, and the constant act of keeping their diabetes in balance.
Meet Sena from Japan
Sena felt unsure about her future upon being diagnosed with type 1 but learned to embrace her diabetes while studying abroad and is determined to show the world that diabetes does not define her.
Meet Deanne and Naomi from Canada
Deanne is a resilient mother who has been managing her own diabetes for years. Her experience changed when she began managing her daughter’s diabetes at age 2.
Setting intentions for 2023
It’s been an honor and privilege to serve you in 2022. Thank you for inspiring our team and for showing the world that diabetes does not define you – rather, it makes you stronger.
With reflection and celebration also comes intention setting for what’s next. My commitment to you is that in each and every decision, moment, activity at Medtronic, it is with you at the center so that we can continue to make living life with diabetes easier for you.
Happy holidays to you and your families. I look forward to reconnecting in 2023 on the LOOP blog.
Let’s stay in touch! Update your communication preferences by visiting your profile in Diabetes.shop. Simply login or register your account to ensure you receive communications when and how you want to receive them.
How to set your email preferences
Que Dallara joined Medtronic as EVP and President of the Diabetes business in May of 2022. Before joining Medtronic, Que served as President and CEO of Honeywell Connected Enterprise, Honeywell’s software business. Prior to that, she was SVP and chief commercial officer leading Honeywell’s efforts in brand, strategy, marketing, sales excellence, pricing, product innovation, including enterprise software, data analytics and IoT solutions.
Information provided on this webpage applies to U.S. customers only.
Important safety information: MiniMed™ 770G system with SmartGuard™ technology
The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G System includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose values (SG) and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 770G System consists of the following devices: MiniMed™ 770G Insulin Pump, the Guardian™ Link(3) Transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the Accu- Chek®Guide Test Strips. The system requires a prescription.
The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
|WARNING: Do not use the SmartGuard™AutoMode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard™ Auto Mode.
WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-770g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library
Important safety information: CGM/Guardian™ Connect system
The Guardian™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings in place for accurate operation. A non-functioning mobile device or incorrect settings may prevent the app from issuing alerts. Missing alerts may result in undetected low and high glucose levels. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at https://www.medtronicdiabetes.com/support/download-library/user-guides and https://bit.ly/importantsafety.
Important safety information: Infusion sets
Infusion sets require a prescription and are indicated for the subcutaneous infusion of insulin from an infusion pump. Infusion sets are not indicated for intravenous (IV) infusion or the infusion of blood or blood products. Inaccurate medication delivery, infection and/or site irritation may result from improper insertion and maintenance of the infusion site. Before insertion, clean the insertion site with isopropyl alcohol. Remove the needle guard before inserting the infusion set. If using this infusion set for the first time, do the first set-up in the presence of your healthcare professional. Do not leave air in the infusion set. Prime completely. Follow the instructions provided and replace as indicated in those instructions. For more details, see https://bit.ly/infusionsetsafety.
Important safety information: Reservoir (extended)
The Extended Reservoir requires a prescription and is indicated for the subcutaneous infusion of insulin from compatible Medtronic insulin pumps and infusion sets. Refer to your Medtronic insulin pump user guide for a list of compatible insulins and infusion sets. The reservoir is contraindicated for the infusion of blood or blood products. Use for a maximum of 7 days, or according to the insulin labeling, whichever duration is shorter. For more details, see https://bit.ly/importantsafety.
Important safety information: CareLink™ software
The CareLink™ software is intended for use as a tool to help manage diabetes. The purpose of the software is to take information transmitted from insulin pumps, glucose meters and continuous glucose monitoring systems, and turn it into CareLink™ reports. The reports provide information that can be used to identify trends and track daily activities—such as carbohydrates consumed, mealtimes, insulin delivery, and glucose readings. NOTE: CareLink™ report data is intended for use as an adjunct in the management of diabetes only and NOT intended to be relied upon by itself. Patients should consult their healthcare providers familiar with the management of diabetes prior to making changes in treatment. For more details, please consult https://www.medtronicdiabetes.com/ImportantSafetyInformation and the appropriate CareLink™ User Guide at https://www.medtronicdiabetes.com/support/download-library/user-guides.
Important safety information: combined generic pump and CGM
Medtronic Diabetes insulin infusion pumps, continuous glucose monitoring systems and associated components are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks associated with the use of these systems. Successful operation of the insulin infusion pumps and/or continuous glucose monitoring systems requires adequate vision and hearing to recognize alerts and alarms.
Medtronic Diabetes Insulin Infusion Pumps
Insulin pump therapy is not recommended for individuals who are unable or unwilling to perform a minimum of four blood glucose tests per day. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately.
Medtronic Diabetes Continuous Glucose Monitoring (CGM) Systems
The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a home glucose meter. A confirmatory finger stick is required prior to treatment.
Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected.
Please visit www.medtronicdiabetes.com/about/safety.html for additional details.
Important safety information: One-press serter
The serter is used as an aid for inserting the sensor. It is indicated for single-patient use.
, diabetes management
, end of year
, managing diabetes
, medtronic champion
, medtronic community
, Que Dallara